AKRO:NSD-Akero Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 26.65

Change

+0.09 (+0.34)%

Market Cap

USD 1.20B

Volume

0.43M

Avg Analyst Target

USD 33.75 (+26.64%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AKRO Stock Forecast & Price:
Based on the Akero Therapeutics Inc stock forecasts from 4 analysts, the average analyst target price for Akero Therapeutics Inc is USD 33.75 over the next 12 months. Akero Therapeutics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Akero Therapeutics Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Akero Therapeutics Inc’s stock price was USD 26.65. Akero Therapeutics Inc’s stock price has changed by +1.45% over the past week, +124.14% over the past month and +10.86% over the last year.

About Akero Therapeutics Inc (AKRO:NSD)

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+8.91 (+1.30%)

USD74.83B 13.56 10.63
VRTX Vertex Pharmaceuticals Inc

+7.96 (+2.88%)

USD72.69B 23.18 15.56
MRNA Moderna Inc

+2.54 (+2.12%)

USD48.37B 3.83 2.59
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+2.65 (+2.08%)

USD31.55B 2.99 1.31
RPRX Royalty Pharma Plc

+0.35 (+0.88%)

USD27.26B 39.16 19.50
SGEN Seagen Inc

+0.08 (+0.06%)

USD24.95B 55.02 -36.47
ALNY Alnylam Pharmaceuticals Inc

+5.22 (+2.64%)

USD23.69B N/A -31.40
GMAB Genmab AS

+0.30 (+0.95%)

USD21.80B 40.29 3.47
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AKRO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 26.00% 93% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.00% 93% A 96% A
Trailing 12 Months  
Capital Gain 15.57% 93% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.57% 93% A 94% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -2.52% 57% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.52% 57% F 34% F
Risk Return Profile  
Volatility (Standard Deviation) 37.14% 64% D 43% F
Risk Adjusted Return -6.80% 57% F 41% F
Market Capitalization 1.20B 88% B+ 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 8.18 48% F 75% C
Price/Book Ratio 8.11 13% F 10% F
Price / Cash Flow Ratio -15.09 88% B+ 73% C
EV/EBITDA -9.37 91% A- 82% B-
Management Effectiveness  
Return on Equity -59.80% 48% F 24% F
Return on Invested Capital -47.16% 54% F 25% F
Return on Assets -32.58% 39% F 14% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 22.04 4% F 2% F
Short Percent 20.36% 5% F 6% F
Beta 0.56 78% C+ 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.